P

Inventor

FRENDEWEY DAVID

US56 patents
⚠️ This page may combine multiple inventors who share the name “FRENDEWEY DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

45 patents
US9228208B2Jan 5, 2016

Methods and compositions for the targeted modification of a genome

REGENERON PHARMA79 citations98
US8697851B2Apr 15, 2014

MiRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA91 citations98
US7659442B2Feb 9, 2010

Method for making homozygous genetic modifications

REGENERON PHARMA239 citations98
US7576259B2Aug 18, 2009

Method for making genetic modifications

REGENERON PHARMA236 citations98
US7294754B2Nov 13, 2007

Method for generating an animal homozygous for a genetic modification

REGENERON PHARMA445 citations98
US8354389B2Jan 15, 2013

miRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA56 citations97
US10208317B2Feb 19, 2019

Methods and compositions for the targeted modification of a mouse embryonic stem cell genome

REGENERON PHARMA15 citations94
US9546384B2Jan 17, 2017

Methods and compositions for the targeted modification of a mouse genome

REGENERON PHARMA31 citations94
US10329582B2Jun 25, 2019

Genetic modification of rats

REGENERON PHARMA25 citations93
US8846402B2Sep 30, 2014

Method for genetically modifying isolated non-human mammalian cell by homologous recombination

REGENERON PHARMA17 citations93
US10039269B2Aug 7, 2018

Methods and compositions for generating a mouse

REGENERON PHARMA10 citations92
US9730434B2Aug 15, 2017

Methods and compositions for generating a mouse

REGENERON PHARMA11 citations92
US9414575B2Aug 16, 2016

Methods and compositions for generating a mouse

REGENERON PHARMA12 citations92
US8946504B2Feb 3, 2015

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA10 citations92
US8946505B2Feb 3, 2015

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA10 citations92
US10711280B2Jul 14, 2020

Methods and compositions for the targeted modification of a mouse ES cell genome

REGENERON PHARMA5 citations84
US10301646B2May 28, 2019

Nuclease-mediated targeting with large targeting vectors

REGENERON PHARMA12 citations84
US9834786B2Dec 5, 2017

Nuclease-mediated targeting with large targeting vectors

REGENERON PHARMA13 citations84
US9410163B2Aug 9, 2016

Promoter-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA3 citations84
US10106820B2Oct 23, 2018

Methods and compositions for modifying a targeted locus

REGENERON PHARMA6 citations83
US9902971B2Feb 27, 2018

Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation

REGENERON PHARMA5 citations83
US9267152B2Feb 23, 2016

MiRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA4 citations83
US9096870B2Aug 4, 2015

miRNA-regulated differentiation-dependent self-deleting cassette

REGENERON PHARMA6 citations83
US9398762B2Jul 26, 2016

Production of fertile XY female animals from XY ES cells

REGENERON PHARMA7 citations82
US10781453B2Sep 22, 2020

Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus

REGENERON PHARMA6 citations79
US10457960B2Oct 29, 2019

Methods and compositions for targeted genetic modification using paired guide RNAs

REGENERON PHARMA5 citations73
US10344299B2Jul 9, 2019

Compositions and methods for modifying cells

REGENERON PHARMA3 citations73
US10894965B2Jan 19, 2021

Genetic modification of rats

REGENERON PHARMA2 citations72
US10294494B2May 21, 2019

Methods and compositions for modifying a targeted locus

REGENERON PHARMA2 citations72
US10023916B2Jul 17, 2018

Markers of tumor cell response to anti-cancer therapy

REGENERON PHARMA5 citations72
US10793874B2Oct 6, 2020

Methods and compositions for targeted genetic modifications and methods of use

REGENERON PHARMA4 citations71
US9885058B2Feb 6, 2018

Production of fertile XY female mice from XY mouse ES cells

REGENERON PHARMA2 citations71
US9655351B2May 23, 2017

Production of fertile XY female animals from XY ES cells

REGENERON PHARMA3 citations71
US12110502B2Oct 8, 2024

Models of tauopathy

REGENERON PHARMA1 citations69
US11845957B2Dec 19, 2023

Models of tauopathy

REGENERON PHARMA2 citations69
US11820997B2Nov 21, 2023

Methods and compositions for the targeted modification of a genome

REGENERON PHARMA0 citations63
US12065661B2Aug 20, 2024

Genetic modification of rats

REGENERON PHARMA0 citations62
US11697828B2Jul 11, 2023

Methods and compositions for targeted genetic modification using paired guide RNAs

REGENERON PHARMA1 citations62
US12060571B2Aug 13, 2024

Methods and compositions for modifying a targeted locus

REGENERON PHARMA1 citations61
US11547100B2Jan 10, 2023

Method for screening gene expression in lincRNA-deficient mice or rats

REGENERON PHARMA0 citations61
US11021719B2Jun 1, 2021

Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo

REGENERON PHARMA1 citations61
US12391920B2Aug 19, 2025

Models of tauopathy

REGENERON PHARMA0 citations59
US12041918B2Jul 23, 2024

Production of fertile XY female animals by silencing of genes on the Y chromosome

REGENERON PHARMA0 citations59
US10893666B2Jan 19, 2021

Production of fertile XY female animals by silencing of genes on the Y chromosome

REGENERON PHARMA1 citations59
US11891618B2Feb 6, 2024

Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use

REGENERON PHARMA0 citations56

ECONOMIDES ARIS N

2 patents

FRENDEWEY DAVID

1 patent

POUEYMIROU WILLIAM

1 patent

AUERBACH WOJTEK

1 patent

Showing the top 50 of 56 patents by PatentIndex Score.